CA
NZ
UK
AU
IND
US
…
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bone Biologics Corp is a Nasdaq-listed biotechnology company; public disclosures about its operating activities and product pipeline are limited. Long-term growth may depend on clinical and regulatory progress, successful commercialization or licensing deals, and the ability to scale operations, so investors may find exposure to potential upside tied to milestone-driven value creation.
Material risks include development and regulatory failure, limited operating history and liquidity, reliance on external financing with dilution risk, and competitive and commercialization execution challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.11M | -4.11M | -8.95M | -1.48M | -1.61M |
| Net income | -3.11M | -4.11M | -8.95M | 0.70M | -1.61M |
| Selling general administrative | 2.17M | 2.09M | 2.52M | 2.09M | 1.02M |
| Selling and marketing expenses | - | - | 2.52M | - | - |
| Gross profit | - | - | 0.00M | 0.00M | 0.00M |
| Ebit | - | -4.11M | -8.95M | -3.67M | -1.10M |
| Ebitda | -3.11M | 0.11M | 0.48M | -4.40M | -1.10M |
| Depreciation and amortization | - | 4.22M | 9.43M | -0.73M | 0.30M |
| Operating income | -3.23M | -4.22M | -9.43M | -3.67M | -1.10M |
| Other operating expenses | 3.23M | 4.22M | 9.43M | 3.67M | 1.10M |
| Interest expense | - | - | 2.18M | -2.18M | 0.81M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 0.12M | 0.06M | 0.00M | - | - |
| Net interest income | 0.12M | 0.06M | -0.73M | -0.73M | -0.81M |
| Income tax expense | - | -7.32M | -2.18M | -2.18M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 3.23M | 4.22M | 9.43M | 3.67M | 1.10M |
| Cost of revenue | - | - | 0.00M | 0.00M | 0.00M |
| Total other income expense net | 0.13M | 0.11M | 0.48M | 2.18M | -0.51M |
| Net income from continuing ops | -3.11M | -4.11M | -6.51M | -1.48M | -1.61M |
| Net income applicable to common shares | - | - | - | - | -1.61M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.80M | 3.86M | 3.74M | 8.50M | 6.68M |
| Other current assets | 0.45M | 1.07M | 0.71M | - | - |
| Total liab | 0.42M | 0.38M | 0.83M | 2.55M | 0.10M |
| Total stockholder equity | 5.38M | 3.48M | 2.91M | 5.95M | 6.58M |
| Other current liab | 0.00M | 0.00M | 0.47M | 2.55M | - |
| Common stock | 0.00M | 0.00M | 0.00M | 0.02M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.02M | 0.01M |
| Retained earnings | -88.13M | -85.02M | -80.91M | -71.96M | -70.48M |
| Other assets | - | - | - | 0.00M | - |
| Cash | 5.33M | 3.33M | 3.03M | 7.54M | 6.68M |
| Total current liabilities | 0.42M | 0.38M | 0.83M | 2.55M | 0.10M |
| Net debt | -5.33M | -3.33M | -3.03M | -7.54M | -6.68M |
| Other stockholder equity | 93.51M | 88.50M | 83.81M | 77.89M | 77.04M |
| Total current assets | 5.80M | 3.86M | 3.74M | 8.50M | 6.68M |
| Net tangible assets | - | - | - | - | 6.58M |
| Net receivables | 0.01M | - | 0.33M | - | - |
| Inventory | - | - | -0.33M | - | - |
| Accounts payable | 0.42M | 0.37M | 0.36M | 0.00M | 0.10M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | - | -0.37M |
| Net borrowings | - | - | - | - | 1.05M |
| Total cash from financing activities | 4.70M | 4.42M | 5.04M | 4.43M | 7.90M |
| Change to operating activities | - | - | - | - | 0.04M |
| Net income | -3.11M | -4.11M | -8.95M | -1.48M | -1.61M |
| Change in cash | 2.01M | 0.30M | -4.51M | 0.86M | 6.68M |
| Begin period cash flow | 3.33M | 3.03M | 7.54M | 6.68M | 0.00M |
| End period cash flow | 5.33M | 3.33M | 3.03M | 7.54M | 6.68M |
| Total cash from operating activities | -2.69M | -4.12M | -9.56M | -3.57M | -1.23M |
| Issuance of capital stock | 4.70M | 2.62M | 8.88M | 4.43M | 6.86M |
| Dividends paid | - | 3.21M | - | - | - |
| Change to account receivables | -0.01M | - | - | - | - |
| Other cashflows from financing activities | 4.70M | 5.02M | 0.01M | 4.43M | 1.06M |
| Change to netincome | - | - | - | - | 0.70M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.17M | -0.15M | 0.13M | -0.17M | -0.32M |
| Stock based compensation | 0.26M | 0.19M | 0.15M | 0.27M | 0.21M |
| Other non cash items | -0.00M | -0.05M | -0.89M | -2.18M | 0.50M |
| Free cash flow | -2.69M | -4.12M | -9.56M | -3.57M | -1.23M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| BBLG Bone Biologics Corp |
0.01 3.00% |
0.33 | - | - | - | 0.46 | 0.13 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
2 Burlington Woods Drive, Burlington, MA, United States, 01803
781 552 4452
2
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey Frelick | CEO & Pres | 1966 |
| Ms. Deina H. Walsh | Chief Financial Officer | 1964 |
| Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board | NA |
| Mr. Jeffrey Frelick | CEO & President | 1966 |
| Ms. Deina H. Walsh CPA | Chief Financial Officer | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...